Sign in

Research summary ·

Classification performance of the 2023 ACR/EULAR antiphospholipid syndrome criteria: a systematic review and meta-analysis.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This study looked at a set of rules for antiphospholipid syndrome, or APS. Groups called ACR and EULAR wrote these rules in 2023. The rules are meant to sort cases, not to diagnose them. The team pooled the results of past studies that tested the rules. They searched for work from August 2023 to May 2026. Each study checked the new rules against a doctor's view or the older 2006 rules.

What they found

The review took in 25 data sets. Of these, 13 also had people without APS. The score for picking up true cases was 0.74. The rules almost never put people without APS in the APS group. That score was 0.99. How well the rules picked up cases varied a lot between studies. They picked up few cases of APS linked to pregnancy. Those scores were 0.20 or 0.31, based on which studies were used. They picked up more cases of APS with blood clots. That score was 0.82. Missed cases mostly had only IgM antibodies or pregnancy-type APS.

What it means for patients

The authors say the rules are very good at leaving out people without APS. But the rules miss some people who do have APS. How many they miss depends on the type of APS. The authors say this backs the use of the rules for sorting cases. They say the rules are not meant for a doctor's diagnosis. They also point to clear limits in some APS groups.

Why it is not certain yet

Results on picking up cases differed a lot from study to study. Only 13 data sets had a group of people without APS. So the score for leaving out people without APS rests on fewer data sets. The abstract does not give details on the quality of each study. A review can only be as good as the studies in it.

Source

Classification performance of the 2023 ACR/EULAR antiphospholipid syndrome criteria: a systematic review and meta-analysis.

PubMed · PMID 42615990

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Antiphospholipid syndrome publications